Browse SPTLC1

Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass membrane protein
Domain PF00155 Aminotransferase class I and II
Function

Serine palmitoyltransferase (SPT). The heterodimer formed with SPTLC2 or SPTLC3 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA. The SPTLC1-SPTLC2-SPTSSB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006643 membrane lipid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006667 sphinganine metabolic process
GO:0006670 sphingosine metabolic process
GO:0006672 ceramide metabolic process
GO:0006684 sphingomyelin metabolic process
GO:0006686 sphingomyelin biosynthetic process
GO:0006914 autophagy
GO:0008654 phospholipid biosynthetic process
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0016042 lipid catabolic process
GO:0016236 macroautophagy
GO:0016239 positive regulation of macroautophagy
GO:0016241 regulation of macroautophagy
GO:0019216 regulation of lipid metabolic process
GO:0019751 polyol metabolic process
GO:0030148 sphingolipid biosynthetic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0034311 diol metabolic process
GO:0034312 diol biosynthetic process
GO:0044242 cellular lipid catabolic process
GO:0044283 small molecule biosynthetic process
GO:0045834 positive regulation of lipid metabolic process
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046467 membrane lipid biosynthetic process
GO:0046511 sphinganine biosynthetic process
GO:0046512 sphingosine biosynthetic process
GO:0046513 ceramide biosynthetic process
GO:0046519 sphingoid metabolic process
GO:0046520 sphingoid biosynthetic process
GO:0050994 regulation of lipid catabolic process
GO:0050996 positive regulation of lipid catabolic process
GO:0061724 lipophagy
GO:0097164 ammonium ion metabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
GO:1904502 regulation of lipophagy
GO:1904504 positive regulation of lipophagy
Molecular Function GO:0004758 serine C-palmitoyltransferase activity
GO:0016408 C-acyltransferase activity
GO:0016409 palmitoyltransferase activity
GO:0016454 C-palmitoyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0030170 pyridoxal phosphate binding
GO:0043168 anion binding
GO:0048037 cofactor binding
Cellular Component GO:0002178 palmitoyltransferase complex
GO:0017059 serine C-palmitoyltransferase complex
GO:0031211 endoplasmic reticulum palmitoyltransferase complex
GO:0035339 SPOTS complex
> KEGG and Reactome Pathway
 
KEGG hsa04071 Sphingolipid signaling pathway
hsa00600 Sphingolipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1660661: Sphingolipid de novo biosynthesis
R-HSA-428157: Sphingolipid metabolism
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SPTLC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SPTLC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.64; FDR: 0.01650 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SPTLC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1310.595
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2670.908
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0280.987
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1160.645
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0610.973
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1860.936
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0850.835
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.020.991
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1920.924
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0340.982
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0420.632
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0860.151
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SPTLC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPTLC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPTLC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPTLC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPTLC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SPTLC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SPTLC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSPTLC1
Nameserine palmitoyltransferase, long chain base subunit 1
Aliases LCB1; SPTI; HSAN1; hLCB1; HSN1; hereditary sensory neuropathy, type 1; LBC1; SPT1; LCB 1; SPT 1; long chain ......
Chromosomal Location9q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SPTLC1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SPTLC1.
ID Name Drug Type Targets #Targets
DB00114Pyridoxal PhosphateSmall MoleculeAADAT, ABAT, AGXT, AGXT2, ALAS1, ALAS2, AZIN2, BCAT1, BCAT2, CBS, ......54
DB00133SerineSmall MoleculeAGXT, CBS, SARS, SDS, SPTLC1, SPTLC2, SRR7